Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Contract research news in brief

October 27, 2010 Research and Development Almac, Kinaxo, MediData Solutions, Quintiles, Ricerca Biosciences, Southern Research Institute, Venn Life Sciences, biofocus, contract research

Our latest crop of contract research news includes updates from Quintiles, Venn Life Sciences, Medidata Solutions, Southern Research Institute, Ricerca …
News

Health outcomes – does anything else matter?

October 27, 2010 Research and Development Les Rose, evidence-based medicine, healthcare outcomes, randomised controlled trials

So the mould of British politics has been broken, and we now have a government with probably a broader range …
Feature

Pharma engages HTA bodies in early-stage drug discussions

October 27, 2010 Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
News

Sanofi moves teriflunomide into phase III MS trials

October 26, 2010 Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide

Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …
News

Conducting clinical trials in China

October 26, 2010 Research and Development China, Jim Wei, Medpace, clinical trials, clinical trials in Chaia, regulatory affairs

As industry pressure to conduct successful global clinical trials on time and on budget continue, tapping emerging global markets will …
Feature

Two thirds of pharma companies face ‘strategic crisis’

October 25, 2010 Research and Development, Sales and Marketing Novartis, Pfizer, Roland Berger, generics, pharma research, pharma sales

The pharma industry is moving away from traditional in-house innovation and toward a more diversified business model, but will encounter …
News

Lilly suspends late-stage trials of diabetes drug Protege

October 22, 2010 Research and Development, Sales and Marketing MacroGenics, Protege, diabetes, lilly, type I diabetes

Eli Lilly and its partner MacroGenics have suspended phase III trials of their investigational type I diabetes drug Protege after …
News

European medicines legislation and pharmacovigilance

October 20, 2010 Research and Development NDA, pharmacovigilance, regulatory affairs

During the past decade, changes in European medicines legislation and guidelines have increased the scope and regulatory scrutiny of pharmacovigilance …
Feature

UK science in line for £500m boost from EU

October 20, 2010 Research and Development UK Biobank, UKCMRI, biotech funding, life sciences, science parks

The European Investment Bank has unveiled a £500 million package of loans to boost the UK’s science and education base …
News
Dr Ben Goldacre

Dr Ben Goldacre: “This is a very broken system”

October 19, 2010 Medical Communications, Research and Development, Sales and Marketing Bad Science, Ben Goldacre, industry reputation, trial data

The pharma industry has its fair share of critics, but unfortunately for everybody, many are easy to dismiss – shrill, …
Feature

GSK collaborates on rare genetic diseases

October 19, 2010 Research and Development Fondazione San Raffaele, Fondazione Telethon, GlaxoSmithKline, Stem cells, gene therapy

GlaxoSmithKline has partnered with one of the biggest biomedical charities in Italy and the country’s largest private research institute to …
News

Bayer’s Xarelto hailed at Prix Galien

October 19, 2010 Research and Development Firazyr, Xarelto, prix galien

Bayer’s Factor Xa anticoagulant Xarelto scooped the Best Pharmaceutical Agent award at the prestigious Prix Galien ceremony. Xarelto is part …
News

Cutting-edge cancer treatments showcased at ESMO

October 18, 2010 Research and Development AstraZeneca, Boehringer, Cancer, Cancer Conference, Johnson & Johnson, Novartis, personalised medicine

The search for a ‘silver bullet’ against cancer has failed, for now, with the battle against the disease turning instead …
Feature

Sanofi signs translational research deal with Harvard

October 18, 2010 Research and Development Harvard, Sanofi-Aventis, academia, translational

Sanofi-Aventis is to collaborate on translational biomedical research with Harvard University in therapy areas such as cancer, diabetes and inflammation. …
News

Trial shows long-term benefits of Novartis’ Aclasta

October 18, 2010 Research and Development, Sales and Marketing Novartis, aclasta, osteoporosis

Novartis has published new data at the annual meeting of the American Society for Bone and Mineral Research in Toronto …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026